SEC ownership of Lexaria Bioscience Corp.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001348362.

Comparable stake leader

ARMISTICE CAPITAL, LLC

Disclosed value leader

ARMISTICE CAPITAL, LLC

Comparable rows

1/18

Latest evidence

30 Sep 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
1 of 18
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Sep 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001348362
Issuer location
Kelowna, British Columbia, Canada

Ownership snapshot

Top shareholders of Lexaria Bioscience Corp. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/18
Latest evidence
30 Sep 2026
13D/G 13F 3/4/5 Lead comparable stake: 8.2% 17 rows are not safely comparable across share classes. 13D/G row: ARMISTICE CAPITAL, LLC Showing 1-8 of 18 holder rows.

Quick read

ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 8.2%.

1 of 18 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership Top 1
ARMISTICE CAPITAL, LLC 8.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 18 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARMISTICE CAPITAL, LLC
13D/G 13F
Company
8.2%
Reported 13D/G · 30 Sep 2026
$554,110
172,084 shares
$0 30 Sep 2026
Christopher Bunka
3/4/5
Director
—
mixed-class rows
$533,006
740,289 shares
mixed-class rows
— 17 Mar 2026
Richard Christopher
3/4/5
Chief Executive Officer, Director
—
mixed-class rows
$363,611
415,000 shares
mixed-class rows
— 29 Jul 2025
John Martin Docherty
3/4/5
President & CSO, Director
—
mixed-class rows
$322,458
370,285 shares
mixed-class rows
— 29 Jul 2025
Michael Elliot Shankman
3/4/5
Chief Financial Officer
—
denominator unverified
$122,000
100,000 shares
— 15 May 2025
Nicholas W. Baxter
3/4/5
Director
—
mixed-class rows
$90,280
74,000 shares
mixed-class rows
— 15 May 2025
William Edward McKechnie
3/4/5
Director
—
mixed-class rows
$71,296
81,191 shares
mixed-class rows
— 29 Jul 2025
Invenomic Capital Management LP
13F
Company
13F
—
denominator unverified
$67,971
21,578 shares
— 30 Sep 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 20 Nov 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-12 of 12 reporting-owner rows connected to Lexaria Bioscience Corp.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
12
Largest Forms 3/4/5 holder
Christopher Bunka
Net 12M change
$0
Latest report
17 Mar 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Christopher Bunka Director $533,006 Mixed 17 Mar 2026
Richard Christopher Chief Executive Officer, Director $363,611 Mixed 29 Jul 2025
John Martin Docherty President & CSO, Director $322,458 Mixed 29 Jul 2025
Michael Elliot Shankman Chief Financial Officer $122,000 Mixed 15 May 2025
Nicholas W. Baxter Director $90,280 Mixed 15 May 2025
William Edward McKechnie Director $71,296 Mixed 29 Jul 2025
Vanessa Carle Secretary $65,932 Mixed 29 Jul 2025
Albert L. Reese Jr. Director $65,778 Mixed 15 May 2025
Baljinder Bhullar Director $15,860 Mixed 15 May 2025
Catherine C. Turkel Director $9,703 Filing P/S 12 Aug 2024
Gregory Downey Chief Financial Officer $4,084 Filing P/S 14 Oct 2022
Nelson Cabatuan Chief Financial Officer Mixed 14 Mar 2024

Recent insider transactions for Lexaria Bioscience Corp.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Christopher Bunka LEXX common shares Gift -26.8% -100,000 273,543 17 Mar 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .